Disc Medicine (IRON) reported that its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints. The company plans to resubmit an NDA by end of 2026 with an FDA decision expected by mid-2027. The stock was halted pending the announcement.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
